Plasma Exchange and Intravenous Immunoglobulin in Autoimmune Myasthenia Gravis^a

Establishment of a national on-line registry for apheresis in Korea

“…Neurologic disorders decreased from 18.8% to 11.7%, with decrease in myasthenia gravis from 15.3% to 10.2%. Similar changes have been reported in other countries [4,6] possibly due to the conclusions of various therapeutic studies [18,19]. The overall response rate to therapeutic plasmapheresis was 86.5% among 793 patients whose clinical outcome was assessable by this on-line registry, which is slightly higher than that reported by other countries (82.3% of total patients assessable) [11].…”

IV immunoglobulin in patients with myasthenia gravis

“…These findings are consistent with results from a previous unmasked study showing a comparable benefit of IVIG and plasma exchange at 1 and 4 weeks post treatment in patients with severe symptoms of MG requiring intensive care. 7 This study supports therapeutic strategies for the treatment of patients with MG. One course of IVIG treatment given over 2 days produced a clinically meaningful benefit at least 4 weeks post treatment. In patients with more severe disease who cannot tolerate immunosuppressive therapy, IVIG treatments every 4 weeks may be a viable treatment option akin to patients with immune-mediated neuropathies who are maintained on IVIG alone.…”

Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis

“…He subsequently responded to IVIg therapy. Various studies have reported IVIg to be as efficacious as PE for induction of remission in MG patients [24][25][26]. In our centre PE is the preferred mode of treatment for MG as it is cheaper for the patient, despite higher incidence of complications.…”